TxCell is exclusively developing regulatory T cells that are specific of a single antigen.
As shown below, our general process starts with a simple blood collection. From this blood sample, we produce antigen-specific Treg cells and then expand them before injecting them back to the patient.
Our dual platform has the potential to address a wide range of severe inflammatory and autoimmune disorders with unmet medical needs. TxCell’s current targets include transplant rejection, Crohn’s disease, lupus nephritis, bullous pemphigoid and multiple sclerosis.